CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Dasatinib (BMS-354825)drug
Likely dose
Dasatinib (BMS-354825) 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00364286
NCT00364286Phase 2Completed
CompareCT.gov

Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

M.D. Anderson Cancer Center·interventional·Posted Aug 15, 2006·Updated Jan 20, 2026

In Brief

A Phase 2 clinical trial evaluating Dasatinib (BMS-354825) for Leukemia and Lymphoma. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if dasatinib can help to control Chronic Lymphocytic Leukemia (CLL). The safety of the drug will also be studied. Optional Procedures: You will be asked to have additional blood samples drawn. These samples will be used to see how the disease is responding to the drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2006
Enrollment StartAug 1, 2006
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 19.9 years ago

Interventions

Dasatinib (BMS-354825)drug

50mg Orally twice daily